Amarin Corporation PLC (AMRN) Informed by FDA of October 16th Advisory Committee Date in Connection With Supplemental New Drug Application (sNDA) for Vascepa® in the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia
6/19/2013 9:32:05 AM
More...
|
As if Amarin Corporation PLC (AMRN) Needs Another Worry, Here Comes a Vascepa FDA Panel
6/7/2013 8:08:12 AM
More...
|
Amarin Corporation PLC (AMRN) to Present at the Jefferies and Co. 2013 Global Healthcare Conference
5/31/2013 9:45:46 AM
More...
|
Amarin Corporation PLC (AMRN) Announces Additional Effects of Vascepa® on Lipoprotein Particle Concentration From the ANCHOR Study Presented at the National Lipid Association 2013 Annual Scientific Sessions
5/30/2013 10:04:25 AM
More...
|
Doc Claims SummerStreet's Amarin Corporation PLC (AMRN) Report is Inaccurate
5/29/2013 7:43:03 AM
More...
|
Amarin Corporation PLC (AMRN) Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa® and Statin Therapy
5/22/2013 9:50:18 AM
More...
|
Amarin Corporation PLC (AMRN) Reports First Quarter 2013 Financial Results and Provides Update on Operations
5/10/2013 9:31:38 AM
More...
|
Amarin Corporation PLC (AMRN) Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia
4/23/2013 11:52:14 AM
More...
|
Amarin Corporation PLC (AMRN) Announces Approval of Supplemental New Drug Application for Chemport as Additional Vascepa® Active Pharmaceutical Ingredient Supplier
4/18/2013 11:34:44 AM
More...
|
Amarin Corporation PLC (AMRN) Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa®
4/8/2013 11:28:55 AM
More...
|
|